Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00070122 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 3
- Development phase
- 2,200
- Enrollment target
NCT00070122: Clinical Trial Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT00070122 is a Phase 3 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 2,200 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00070122, a Phase 3 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2,200 participants
- Enrollment target
Study Summary
Drugs used in chemotherapy, such as oxaliplatin, leucovorin, fluorouracil, and capecitabine, work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells. It is not yet known which combination chemotherapy regimen with bevacizumab works better in treating colorectal cancer. This randomized phase III trial is studying giving two different combination chemotherapy regimens together with bevacizumab and comparing how well they work in treating patients with locally advanced, metastatic, or recurrent colorectal cancer
Interventions
- DRUG oxaliplatin
- DRUG fluorouracil
- DRUG capecitabine
- DRUG leucovorin calcium
- BIOLOGICAL bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,200 participants |
| Start Date | 2004-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00070122
The ClinicalTrials.gov registry entry for NCT00070122 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 2,200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which oxaliplatin is the first listed.
NCT00070122 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00070122 about?
NCT00070122 is a clinical study titled "Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer". Drugs used in chemotherapy, such as oxaliplatin, leucovorin, fluorouracil, and capecitabine, work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer ...
What is the current status of trial NCT00070122?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2,200 participants. The study started on 2004-04.
What interventions are being tested in trial NCT00070122?
The interventions under investigation include: oxaliplatin (DRUG), fluorouracil (DRUG), capecitabine (DRUG), leucovorin calcium (DRUG), bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00070122?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.